ELUTIA INC (ELUT)
(Delayed Data from NSDQ)
$4.03 USD
+0.02 (0.50%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $3.99 -0.04 (-0.99%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ELUT 4.03 +0.02(0.50%)
Will ELUT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ELUT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELUT
Are Medical Stocks Lagging DiaMedica Therapeutics (DMAC) This Year?
Beat the Market Like Zacks: Karooooo, UnitedHealth, Amgen in Focus
ELUT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks.com featured highlights BRC, Costamare and Elutia
3 Best Breakout Stocks Worth a Buy for Attractive Returns
Elutia Inc. (ELUT) Upgraded to Buy: Here's Why
Other News for ELUT
Elutia Inc. 2024 Q2 - Results - Earnings Call Presentation
Elutia Inc. (ELUT) Q2 2024 Earnings Call Transcript
Analysts Have Conflicting Sentiments on These Healthcare Companies: Revolution Medicines (RVMD), Fortrea Holdings Inc. (FTRE) and Aziyo Biologics (ELUT)
Elutia price target lowered by $1 at Cantor Fitzgerald, here's why
Elutia Announces Second Quarter 2024 Results